Tenecteplase Versus Alteplase for Stroke Thrombolysis Evaluation Trial in the Ambulance

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 104 participants.

Also called NCT04071613

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 104 participants (enrolled count) (from the registry)
Sponsor
Melbourne Health (from the registry)
Registry
  • NCT NCT04071613
Other papers using this trial's data
  • Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne Mobile Stroke Unit (TASTE-A): a phase 2, randomised, open-label trial The Lancet. Neurology, 2022-06 DOI, PubMed 35525251

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Australia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04071613. Randomized; single masking; primary purpose treatment. Start 2019-06-20 (actual); primary completion 2021-11-16 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Tenecteplase Versus Alteplase for Stroke Thrombolysis Evaluation Trial in the Ambulance
Acronym
TASTEa
Condition
Stroke, Acute, Stroke Ischemic
Intervention (Drug)
Tenecteplase
Intervention (Drug)
Intravenous tissue plasminogen activator (tPA)
Lead sponsor
Melbourne Health (class: other)

Record details

Record id
cardio:ct-nct04071613
Content hash
3e4f33d9e7ea1499736a3861e082db4204728199b5cb0a0aa36bd4f4d46c8ee5